Immunic, Inc. (NASDAQ:IMUX – Get Rating) CEO Daniel Vitt acquired 5,000 shares of the stock in a transaction on Friday, June 3rd. The shares were acquired at an average price of $3.10 per share, for a total transaction of $15,500.00. Following the acquisition, the chief executive officer now owns 368,877 shares of the company’s stock, valued at approximately $1,143,518.70. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Shares of NASDAQ:IMUX opened at $3.39 on Monday. The firm has a market capitalization of $103.53 million, a PE ratio of -1.08 and a beta of 2.00. Immunic, Inc. has a twelve month low of $2.52 and a twelve month high of $15.12. The company has a 50-day moving average price of $7.88 and a two-hundred day moving average price of $9.77.
IMUX has been the subject of several analyst reports. Piper Sandler lowered their target price on shares of Immunic from $71.00 to $39.00 and set an “overweight” rating for the company in a report on Tuesday, May 17th. Zacks Investment Research downgraded shares of Immunic from a “hold” rating to a “sell” rating in a report on Tuesday, May 3rd. StockNews.com started coverage on shares of Immunic in a report on Thursday, March 31st. They issued a “sell” rating for the company. SVB Leerink reduced their price target on shares of Immunic from $45.00 to $9.00 and set an “outperform” rating for the company in a research report on Friday. Finally, Wedbush reduced their price target on shares of Immunic from $61.00 to $14.00 in a research report on Thursday. Two investment analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $20.00.
Immunic Company Profile (Get Rating)
Immunic, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease.
- Get a free copy of the StockNews.com research report on Immunic (IMUX)
- This Isn’t A Buyable Bottom For Stocks
- Macys Stock is Ready to Buy
- First Solar Stock is Ready to Shine
- Insiders And Institutions Drive Consolidated Edison To New Highs
- MarketBeat: Week in Review 5/30 – 6/3
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.